Neuro-Oncology Reviews

Volume 27 Number 16
10 June 2025

Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 16, 10 June

Chen AG, Do TH, Chen KY, Zhu P.
Robust and Specific Association Between Seizure at Presentation and Improved Survival in Patients With Primary Brain Tumors.
Discov Med. 2025 Jun;37(197):984-993. doi: 10.24976/Discov.Med.202537197.88. PMID: 40485516. Review˰ ˍ

Maitra A, Miciaccia M, Mandorino M, Armenise D, Baldelli OM, Ferorelli S, Papusha L, Druy A, Perrone MG, Scilimati A.
Decoding Gene Expression Changes in Cerebral Tumors: Before and After Radiotherapy.
Med Res Rev. 2025 Jun 1. doi: 10.1002/med.22122. PMID: 40452178. Review. ˍ
>>> Diffuse midline glioma

Gong AD, Dang DD, Awan O, Mugge L, Yokoi H, Cohen AL, Moores L.
Pediatric-type high-grade glioma of the spinal cord in the molecular era: institutional case series and updated systematic review of the literature.
Childs Nerv Syst. 2025 Jun 2;41(1):200. doi: 10.1007/s00381-025-06856-8. PMID: 40455242. Review˰ ˍ

Chan JTN, Henley-Waters J, Kayhanian S.
Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review.
Neurooncol Adv. 2025 Jun 3;7(1):vdaf115. doi: 10.1093/noajnl/vdaf115. PMID: 40626039. Review. ˍ AI Overview

Liu Y, Su C, Wei X, Wei N, Qian Q, Xu Z.
Prospects and applications of NK therapy in the treatment of gliomas (Review).
Oncol Rep. 2025 Jun 3;54(2):88. doi: 10.3892/or.2025.8921. PMID: 40476557. Review. ˍ

Song Z, Yang C, Gu J, Qu R, Xie Y, Guo Y, Nong X, Chen Z, Wang Z.
The hotspots and publication trends in glioblastoma and CAR-T immunotherapy: A bibliometric analysis.
Hum Vaccin Immunother. 2025 Jun 3;21(1):2509483. doi: 10.1080/21645515.2025.2509483. PMID: 40460258. Bibliometric analysis. ˍ

Feng XL, Su G, Wu QH, Jia Q, Zhang ZC.
Research progress of galectins in glioma.
Discov Oncol. 2025 Jun 4;16(1):1003. doi: 10.1007/s12672-025-02318-4. PMID: 40467873. Review. ˍ

Shah S, Lucke-Wold B.
Cell-Intrinsic and Cell-Extrinsic Therapeutic Targets in Glioblastoma: Overcoming Resistance Through Tumor Microenvironment Modulation and Precision Medicine.
World Neurosurg. 2025 Jun 4:124142. doi: 10.1016/j.wneu.2025.124142. PMID: 40480545. Review. ˍ

Kroon LL, Dieleman EMT, Keil VC, van Barreveld M, Dijkgraaf MGW, Topff L, Wagemakers SN, Snijders TJ, Vos MJ, Koekkoek JAF, Stalpers LJA, de Vos FYFL, Brandsma D.
Bevacizumab for symptomatic cerebral radiation necrosis after radiation of high-grade glioma or brain metastases - when and for whom?
Neurooncol Pract. 2025 Jun 5;12(5):747-762. doi: 10.1093/nop/npaf059. PMID: 41080204. Review. ˍ

Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, Zheng Y, Ye C, Li F, Ge S, Yao A, Jia L.
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.
Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4. PMID: 40468460. Review. ˍ

Aman R, Desbassarie F, Lubis AR, Ardiansyah IR.
Prognostic factors and survival of recurrent glioblastoma: a systematic review.
Folia Med (Plovdiv). 2025 Jun 6;67(3). doi: 10.3897/folmed.67.e142227. PMID: 40524591. Review. ˍ

Doniselli FM, Ramos J, Hilario A, Opancina V, van der Hoorn A, Castellano A, van der Molen AJ, Quattrocchi CC, Yousry T, Rovira À; ESMRMB-GREC Working Group; ESNR.
Recommendations on the use of gadolinium-based contrast agents in the diagnosis and monitoring of common adult intracranial tumours.
Eur Radiol. 2025 Jun 6. doi: 10.1007/s00330-025-11646-6. PMID: 40478344. Recommendations˰ ˍ

Qiu Y, Huang S, Peng L, Yang L, Zhang G, Liu T, Yan F, Peng X.
The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.
MedComm (2020). 2025 Jun 6;6(6):e70213. doi: 10.1002/mco2.70213. PMID: 40487748. Review. ˍ

Rudà R, Bruno F, Pellerino A, Pronello E, Soffietti R.
Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.
Expert Opin Pharmacother. 2025 Jun 6:1-13. doi: 10.1080/14656566.2025.2516617. PMID: 40479721. Review˰ ˍ

Xia P.
The significance of epithelial-mesenchymal transition (EMT) in the initiation, plasticity, and treatment of glioblastoma.
Genes Dis. 2025 Jun 6;13(1):101711. doi: 10.1016/j.gendis.2025.101711. PMID: 41141394. Review. ˍ

He J, Yan X, Hu S.
Glioma stem cells: drivers of tumor progression and recurrence.
Stem Cell Res Ther. 2025 Jun 7;16(1):293. doi: 10.1186/s13287-025-04352-z. PMID: 40483525. Review. ˍ